The present invention describes novel nitrosated and/or nitrosylated
taxanes, and novel compositions comprising at least one nitrosated and/or
nitrosylated taxane, and, optionally, at least one compound that donates,
transfers or releases nitric oxide, elevates endogenous levels of
endothelium-derived relaxing factor, stimulates endogenous synthesis of
nitric oxide or is a substrate for nitric oxide synthase and/or at least
one therapeutic agent. The present invention also provides novel
compositions comprising at least one taxane and at least one compound that
donates, transfers or releases nitric oxide, elevates endogenous levels of
endothelium-derived relaxing factor, stimulates endogenous synthesis of
nitric oxide or is a substrate for nitric oxide synthase and/or at least
one therapeutic agent. The compounds and compositions of the present
invention can also be bound to a matrix. The present invention also
provides methods for treating or preventing cardiovascular diseases and
disorders, autoimmune diseases, pathological conditions resulting from
abnormal cell proliferation, polycystic kidney disease, inflammatory
disease, preserving organs and/or tissues or to inhibit wound contraction,
particularly the prophylactic and/or therapeutic treatment of restenosis,
by administering nitrosated and/or nitrosylated taxane or parent taxanes
in combination with nitric oxide donors that are capable of releasing
nitric oxide or indirectly delivering or transferring nitric oxide to
targeted sites under physiological conditions.
